KRAS and laryngotracheoesophageal cleft: Hence, our results encourage further studies in a larger cohort of Rn-exposed LC patients to highlight the potential correlation between Rn exposure and MET mutations as well as KRAS mutations and inclusion of Rn-exposed LC patients within the screening for trials investigating MET and KRAS inhibitors.